Tel Aviv (Israel) University researchers generated functional spinal cord, cardiac, cortical and adipogenic tissue implants from personalized hydrogels, according to results detailed in Advanced Materials.

Cellect Biotechnology is a regenerative medicine company.

Bio2 Technologies received FDA approval to begin enrolling patients in an investigational device exemption clinical study to evaluate Vitrium as a cervical interbody fusion device.

Joost de Bruijn, PhD, is the CEO of Kuros Biosciences.

Histogenics develops restorative cell therapies for orthopedic pain relief.

Imagion Biosystems is commercializing a form of medical imaging that uses biosafe nanoparticles to detect cancer, according to Proactive Investors Australia.

Regenerative medicine company SpinalCyte was issued new patents in Hong Kong and Europe.

Guy Cook is the CEO of Lattice Biologics.

Cellect Biotechnology received several patent grants for its Apograft technology.

OsteoRemedies launched the first FDA-cleared dual-antibiotic spacer system and bone cement offering with gentamicin and vancomycin.  

MTF Biologics and Academy Medical partnered to bring human allograft tissues to Veteran Affairs medical centers across the U.S.

ORTHOReBIRTH USA signed a letter of intent to develop new biologic products with Loubert Suddaby, MD.

The Tobra Medical Bone Basket is designed to help surgeons maximize the collection of autologous bone during drilling for bone graft.

Orthopedic surgeon Sunny Patel, MD, performed a new knee cartilage replacement procedure at Burlington, N.C.-based Alamance Regional Medical Center, the Times-News reports.

Biological Industries USA and StemExpress partnered to distribute StemExpress' human bone marrow-derived mesenchymal stem cells.

Cytokines present in umbilical cord blood-derived products can stimulate cellular processes necessary for bone regeneration, according to a study in Regenerative Medicine.

The global orthobiologics market is projected to reach $10.1 billion by 2025, according to Market Insights Reports.

Anika Therapeutics appointed Susan Vogt to its board of directors.

Degenerative disc disease patients who received intradiscal injections of SpinalCyte's CybroCell showed sustained pain relief improvement and greater back mobility after 12 months, according to the results of a phase 1/2 clinical trial.

Regentis Biomaterials expanded its clinical trial of GelrinC for the treatment of articular knee cartilage damage to 11 U.S. sites.